BriaCell Therapeutics plans to acquire Sapientia Pharmaceuticals through its subsidiary BriaCell Therapeutics (BriaCell USA).

BriaCell Therapeutics is a biotechnology company based in Canada, while Sapientia is a US-based biotechnology company.

Go deeper with GlobalData

Go deeper with GlobalData

The gold standard of business intelligence.

Find out more

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

The acquisition will enable BriaCell to expand its drug discovery capabilities and broaden its pipeline.

"Miltenyi Biotec subsidiary Lentigen Technology has announced the acquisition of personalised chimeric antigen receptor (CAR) T-cell therapy developer, Living Pharma."

Miltenyi Biotec subsidiary Lentigen Technology has announced the acquisition of personalised chimeric antigen receptor (CAR) T-cell therapy developer, Living Pharma.

The acquisition will enable Lentigen to progress the development of its CAR T-cell therapies.

Both the target and the acquirer companies are based in the US.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact